Phase II Study Of Niraparib In Patients With PALB2 Mutated Locally Advanced Or Metastatic Solid Tumors, Including Pancreatic Cancer
Summary
The purpose of this phase II study is to evaluate the safety and efficacy of niraparib in patients with locally advanced or metastatic PALB2 (tPALB2) mutation solid tumors, including pancreatic cancer.
General Information
NCT#: NCT05169437
Study ID: TMPS-101
Trial Phase: Phase II
Trial Sponsor: Tempus Labs
Therapies Used in This Trial: Niraparib